NouvNeu002
Ischemic Stroke
PreclinicalIND planned for Q4 2026
Key Facts
About iRegene Therapeutics
A biotech company developing iPSC-based cell therapies for neurological and retinal diseases using an AI-integrated discovery platform.
View full company profileTherapeutic Areas
Other Ischemic Stroke Drugs
| Drug | Company | Phase |
|---|---|---|
| dl-3-n-Butylphthalide (NBP) Soft Capsules | CSPC Pharmaceutical | Phase 3 |
| MultiStem | Athersys | Phase 3 |
| IQool™ System | BrainCool | Clinical Evaluation |
| itMSCs + itNSCs | Stemedica Cell Technologies | Research |
| BXT-25 | BioXyTran | Preclinical |
| Ischemic Stroke Program | CHS Pharma | Pre-clinical |
| 3K3A-APC | ZZ Biotech | Phase 2/3 |
| Ischemic Stroke Device(s) | Infinity Neuro | Pre-clinical |
| THDG3 | DeckTherapeutics | Pre-clinical |
| Prometheus-based Gene Therapy | Remedium Bio | Pre-clinical |
| iNstroke Catheters | iVascularU | Commercial |
| Dual Thrombolytic Regimen (tPA + HisproUK) | Thrombolytic Science International | Phase 2 |